Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil

Full text
Author(s):
Show less -
de Melo, Andreia Cristina [1] ; de Sa, Vanessa Karen [2] ; Sternberg, Cinthya [1] ; Olivieri, Eloisa Ribeiro [3] ; da Cunha, Isabela Werneck [3] ; Fabro, Alexandre Todorovic [2] ; Carraro, Dirce Maria [3] ; de Barros e Silva, Milton Jose [1] ; Pimenta Inada, Haynna Kimie [1] ; de Mello, Evandro Sobrosa [4] ; Soares, Fernando Augusto [3] ; Takagaki, Tereza [5] ; Ferreira, Carlos Gil [1] ; Capelozzi, Vera Luiza [2]
Total Authors: 14
Affiliation:
[1] Natl Canc Inst, Rio De Janeiro - Brazil
[2] Univ Sao Paulo, Fac Med, Dept Pathol, BR-01296903 Sao Paulo, SP - Brazil
[3] AC Camargo Canc Ctr, Ctr Int Pesquisa, Sao Paulo - Brazil
[4] Univ Sao Paulo, Div Pulm, Canc Inst State Sao Paulo, BR-01296903 Sao Paulo, SP - Brazil
[5] Univ Sao Paulo, Div Pulm, Heart Inst InCor, BR-01296903 Sao Paulo, SP - Brazil
Total Affiliations: 5
Document type: Journal article
Source: ONCOLOGY; v. 89, n. 3, p. 175-186, 2015.
Web of Science Citations: 10
Abstract

Aim: To show additional prognostic information about the mutational profile and new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) classification of adenocarcinoma (ADC) in patients without epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatments. Methods: In human lung ADC patients (n = 125), including 24 lepidic, 67 acinar, 23 papillary, and 11 solid predominant subtypes, EGFR and KRAS were sequenced, and anaplastic lymphoma kinase (ALK) rearrangements were screened using fluorescence in situ hybridization (FISH). Results: EGFR was mutated in 21.6% of patients with 19.57% showing a mean expression. The most frequent EGFR mutation was a deletion in exon 19, followed by an L858R amino acid substitution in exon 21. KRAS was mutated in 26.4% of patients with 50% displaying mean expression. ALK rearrangement was detected in 6 patients (4.8%). Predominant acinar ADC was strongly associated with EGFR and KRAS mutation. Clinical stage, lymph node metastases, and EGFR mutation in exon 18 showed a significant difference in disease-free and overall survival, but only a trend significance for EGFR and KRAS mutations. Multivariate analysis revealed that men aged >71 years, with a history of smoking (<72 packs/year), clinical stage I/II, and acinar histologic subtype presented better survival than women aged <= 71 years, with a history of smoking (>72 packs/year), and having a predominant solid ADC and EGFR mutation in exon 18. Conclusions: These results indicate that the mutational profile and new IASLC/ATS/ERS classification provide additional prognostic information about lung ADC. (C) 2015 S. Karger AG, Basel (AU)

FAPESP's process: 11/52095-0 - Evaluation of the frequency of EGFR, KRAS and EML4-ALK mutation in adenocarcinomas and their subtypes and impact of expression of hyaluronidases and hyaluronic acid synthase in pre-neoplastic lung lesions
Grantee:Vera Luiza Capelozzi
Support Opportunities: Regular Research Grants